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Antiretroviral therapy (ART) has transformed the clinical profile of human immunodeficiency virus (HIV) from an acute infection
with a highmortality into a treatable, chronic disease. As a result, the clinical sequelae of HIV infection are changing as patients live
longer.HIV-associated cardiomyopathy (HIVAC) is a stage IV,HIV-defining illness and remains a significant cause ofmorbidity and
mortality amongHIV-infected individuals despite ART. Causes and clinical manifestations of HIVAC depend on the degree of host
immunosuppression. Myocarditis from direct HIV toxicity, opportunistic infections, and nutritional deficiencies are implicated
in causing HIVAC when HIV viral replication is unchecked, whereas cardiac autoimmunity, chronic inflammation, and ART
cardiotoxicity contribute to HIVAC in individuals with suppressed viral loads. The initiation of ART has dramatically changed
the clinical manifestation of HIVAC in high income countries from one of severe, left ventricular systolic dysfunction to a pattern
of subclinical cardiac dysfunction characterized by abnormal diastolic function and strain. In low and middle income countries,
however, HIVAC is themost commonHIV-associated cardiovascular disease. Clear diagnostic and treatment guidelines forHIVAC
are currently lacking but should be prioritized given the global burden of HIVAC.
1. Introduction
Dramatic gains have been made in the treatment of human
immunodeficiency virus (HIV) over the last decade. By 2013,
35 million people globally were infected with HIV, and there
were 2.1 million new HIV infections, nearly 40% lower
than in 2001 [1]. The number of acquired immunodeficiency
syndrome (AIDS) related deaths also declined by 35% over
the same time period [1]. Much of the survival gains seen for
people infected with HIV/AIDS are due to better availability
of antiretroviral therapy (ART). The Joint United Nations
Programme on HIV/AIDS (UNAIDS) estimates that 13.6
million people were receiving ART as of June 2014 and that 15
millionwill receiveARTby 2015 [1]. HIV-infected individuals
on ART can expect to live longer and, as a result, they are
at risk of developing chronic, noncommunicable diseases
including many forms of cardiovascular disease [2].
HIV-associated cardiomyopathy (HIVAC) has evolved
since its first description in themid-1980s [3].Throughout the
1980s and 1990s, before the widespread availability of ART,
the presence of heart failure in HIV-infected individuals was
mainly in the context of myocarditis, related to direct effects
of HIV, opportunistic infections, autoimmunity, nutritional
deficiencies, or severe immunosuppression [4]. HIVAC was
characterized as symptomatic, systolic dysfunction asso-
ciated with a dilated left ventricle and indicated a poor
prognosis for HIV-infected patients. Median survival was 101
days for HIV-infected patients after diagnosis with dilated
cardiomyopathy, compared to 472 days for patients with
normal findings on echocardiogram at a similar stage of
immunosuppression [5]. Today, systolic dysfunction is being
replaced by subclinical diastolic dysfunction as the hallmark
of HIVAC in individuals with well controlled HIV [6].
No consensus criteria currently exist to define “HIV-
associated cardiomyopathy,” but studies have outlined mul-
tiple subtypes of this evolving disease. Manifestations of
HIVAC include symptomatic heart failure with left ven-
tricular dysfunction with or without concurrent ventricular
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Table 1: Etiologies and Characteristic Phenotypes of HIVAC.
Etiology of HIVAC Characteristic HIVAC Phenotype
Uncontrolled HIV Disease:
(i) Immunosuppressed host
(ii) High viral load
(iii) Low CD4 count (<400
cells/mm3)
(i) Myocarditis
(a) Direct HIV toxicity
(b) Opportunistic Infections
(1) Viral: Coxsackie B, CMV, EBV





(i) More commonly seen in LMIC
(ii) Symptomatic, systolic dysfunction +/− dilated
ventricles
(iii) Poor prognosis
Controlled HIV Disease: (i) Cardiac Autoimmunity (i) More commonly seen in HIC
(i) Immunocompetent host (ii) Cardiac inflammation (ii) Subclinical diastolic dysfunction with increased
strain patterns(ii) Undetectable viral load (iii) ART toxicity
(a) AZT-induced cardiomyopathy
dilation, any systolic impairment or diastolic dysfunction
in asymptomatic HIV patients, and new onset heart failure
in stage IV HIV disease [7]. This broadened classification
of HIVAC illustrates the increasingly complex relationship
between HIV and cardiac dysfunction.
This transition in disease profile results from important
disparities in the epidemiology and pathogenesis for HIVAC
between high income countries (HICs) and low and mid-
dle income countries (LMICs), which, to the best of our
knowledge, relate to differences in ART availability, HIV viral
suppression, comorbidities, and opportunistic infections
(Table 1) [6]. Thus, our understanding of the epidemiology
and etiology ofHIVAC in the pre-ART era remains relevant in
many parts of the world where ART availability remains low.
This reviewwill explore the contributing etiologies of HIVAC
while highlighting the current, disparate burden of HIVAC
between HICs and LMICs.
2. Etiology of HIV-Associated Cardiomyopathy
Much of our understanding about the etiology of HIVAC
is derived from studies performed in HICs before the
availability of ART. As a result, the literature focused on
direct and indirect cardiotoxicity of infections and HIV
itself. More recent literature suggests an expanded role of
autoimmunity and drug toxicity in the setting of ART. Studies
fromLMICs have also explored the role of nutrition in disease
development. While large knowledge gaps remain, there are
a number of prevailing hypotheses about the multifactorial
etiology of HIVAC.
2.1. Myocarditis. Myocardial inflammation caused by HIV
and related infections is implicated as a key inciting factor in
the development of HIVAC. Various viral and opportunistic
infections trigger myocarditis in the setting of uncontrolled
HIV infection. Direct invasion of cardiac myocytes by car-
diotropic viruses, including HIV, leads to a local cytokine
release and subsequent infiltration of the myocardium with
clonal expansion of B cells [8]. Myocarditis is particularly
common in late stages of HIV infection. High rates of
myocarditis are associated with CD4 counts of less than 400
cells/mm3 and up to two-thirds of untreated AIDS patients
having histological evidence of myocarditis on autopsy [8, 9].
Both viral and nonviral opportunistic infections have
been linked to myocarditis and subsequent left ventricular
dysfunction in untreated HIV patients. One of the largest
clinical pathology studies done to date found that Italian
patients with AIDS and myocarditis were often coinfected
with cardiotropic viruses, most commonly Coxsackie B3
virus (32%), Epstein-Barr virus (8%), and Cytomegalovirus
(4%) [10, 11]. Even higher rates ofCytomegalovirus (48%) have
been seen in patients with left ventricular dysfunction using
in situ hybridization [12]. Toxoplasma gondii, Cryptococcus
neoformans, and Mycobacterium avium-intracellulare have
also been isolated from the myocardium of end-stage AIDS
patients with evidence of myocarditis and left ventricular
dysfunction on autopsy [13]. Reduction in opportunistic
infections in patients on ART may be responsible for the
impressive drop in myocarditis rates and declining preva-
lence of HIVAC as seen in HICs [14, 15].
It is hypothesized that the HIV-1 virus causes myocarditis
directly through myocyte toxicity, although debate about
the exact pathogenesis exists. In vitro studies of human
and rat cardiomyocytes have shown that HIV can enter
myocytes directly through pathways independent of CCR5
and CXCR4 receptors. Invasion is thought to occur through
macropinocytosis as HIV-1 virion particles with their nucle-
ocapsid cores can be seen in vacuoles within myocytes on
scanning electron microscopy [10, 16, 17]. HIV-1 nucleic
acid sequences can be detected within the myocardial tissue
of HIV-infected patients with myocarditis by in situ DNA
hybridization [12, 18].
HIV also catalyzes a cascade of indirect pathways that
induce myocardial inflammation and damage. Cardiomy-
ocyte apoptosis and myocardial macrophage infiltration
are more common in patients with HIVAC than in HIV-
infected patients without cardiomyopathy [17]. Cardiomy-
ocyte expression of HIV-1 associated protein, gp-120, and
transactivator of transcription (Tat) protein signaling path-
ways have been implicated in mitochondrial dysfunction and
cardiomyocyte apoptosis [16, 17, 19]. Additionally,myocardial
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dendritic cells including macrophages and endothelial cells
have been considered “reservoir cells” for HIV-1 invasion and
contribute to localized myocardial cell death through acti-
vation of inflammatory cytokines [20]. Macrophages initiate
proapoptotic signaling through mitochondrial injury, acti-
vation of caspases, and receptor-mediated signaling through
tumor necrosis factor- (TNF-) alpha and Fas ligand expres-
sion [16, 17]. The release of TNF-alpha specifically has been
shown to have a negative ionotropic effect on cardiomyocytes
by altering intracellular calcium homeostasis and inducing
nitric oxide synthesis [10]. Myocardial damage from these
indirect pathways ultimately leads to left ventricular systolic
dysfunction, increased left ventricular mass, and expression
of natriuretic peptides that may lead to hemodynamic com-
promise as demonstrated in vivo in rats [21].
2.2. Cardiac Autoimmunity. Higher levels of serum autoan-
tibody titers have been seen in HIV-infected adults and chil-
dren with myocardial disease compared to HIV-uninfected
individuals. Significantly higher concentrations of anti-alpha
myosin antibodies are found in HIV-infected individuals
compared to HIV-negative controls [22]. The level of car-
diac autoantibodies is progressively higher comparing HIV-
uninfected controls (3%), HIV-infected individuals without
heart disease (19%), and HIV-infected patients with left ven-
tricular systolic dysfunction (43%) [22]. Autoantibody con-
centrations correlate withmortality in HIV-infected patients.
Infection with common and opportunistic viruses may
facilitate the onset of cardiac autoimmunity in HIV-infected
individuals bymodifying cardiomyocyte surface antigens and
exposing otherwise hidden cell surface epitopes, resulting
in abnormal autoimmune responses against endogenous
cardiomyocytes [22]. Persistent, latent myocardial infection
with cardiotropic viruses, like Cytomegalovirus, may trigger
clonal expansion of autoreactive CD8 T cells that target
normal myocytes and lead to myocarditis [12].
2.3. Micronutrient Deficiency. Micronutrient deficiency is
common in HIV-infected individuals due to gut malabsorp-
tion, diarrhea, and wasting syndrome. The resulting free
radical formation and myocardial injury have been linked
to the development of HIVAC. Selenium is the most widely
studied micronutrient deficiency, as it plays a significant
role in other forms of dilated cardiomyopathy. Selenium is
an essential element used in the generation of glutathione
peroxidase, an enzyme which protects lipid membranes from
oxygen radicals and plays a crucial role in the prevention
of myocardial injury [23]. Abnormalities in immunologic
defense, phagocyte function, and T cell response, as seen
with selenium deficiency, predispose to further myocardial
injury [23]. Animal models have shown that selenium-
deficient mice are more susceptible to myocyte damage and
myocarditis when exposed to stressors, such as Coxsackie B
virus [24].
Selenium deficiency has been associated with cardiomy-
opathy in untreated HIV-infected individuals. A prospective
study of 416 HIV-infected patients in Rwanda found that low
serum selenium levels were associated with nearly twice the
odds of developing cardiomyopathy in multivariate analysis
(OR 1.92, 95%CI 1.73–2.04) [25]. Low levels of serum sele-
nium correlate directly with other knownHIVAC risk factors,
including low socioeconomic status and CD4 count [25, 26].
While selenium deficiency may have role in risk of
HIVAC, the role of selenium supplementation in preventing
or treating HIVAC remains unknown. Case reports have
shown improvement in cardiac function with supplemen-
tation in targeted, selenium-deficient patients but, despite
numerous salutary effects of selenium supplementation in
HIV-infected individuals, no prospective evidence exists to
support selenium supplementation for treating or preventing
HIVAC [23, 27–29].
2.4. Antiretroviral Toxicity. In general the initiation of ART
has decreased the prevalence of HIVAC in HIC, although use
of zidovudine (AZT) based regimens may be associated with
greater risk of cardiomyopathy [15, 27]. Zidovudine, a reverse
nucleoside transcriptase inhibitor, inhibits mitochondrial
DNApolymerase, causesmitochondrial damage, and leads to
focal myocardial necrosis [30]. Treatment with AZT is asso-
ciated with reversible, dose-dependent damage to skeletal
and cardiac myocytes [30, 31]. Case reports of HIV-infected
adults in the USA in the early 1990s revealed high rates of
cardiac dysfunction associated with AZT monotherapy that
rapidly reversed with cessation of AZT [32]. Increased left
ventricular mass and peak wall stress have also been noted in
HIV-infected children after treatment with AZT [33]. More
recently, AZT exposure has also been linked to diastolic
dysfunction in HIV-infected subjects [34].
2.5. Tuberculous Myopericarditis. Pericardial disease is often
the first manifestation of cardiac disease in HIV-infected
individuals and carries high mortality in LMICs [35]. Peri-
carditis caused by Mycobacterium tuberculosis (TB) is the
leading cause of pericardial disease in HIV-infected indi-
viduals in highly endemic areas, accounting for up to 70%
of all pericardial effusions and 90% of pericardial effusions
in HIV-infected individuals in parts of Sub-Saharan Africa
(SSA) [35, 36]. HIV infection is the most important predis-
posing factor for TB infection, and HIV infection is thought
to alter the clinical manifestation of pericardial disease
[36]. Direct pericardial invasion in HIV coinfection occurs
through hematogenous spread of TB, unlike indirect lym-
phatic invasive inHIV-uninfected hosts [37]. InHIV-infected
individuals, pericardial TB infection often results in larger
pericardial effusions, more myopericardial involvement, and
less constrictive pericarditis compared to HIV-uninfected
individuals [36]. The Investigation of the Management of
Pericarditis in Africa (IMPI Africa), a registry of 185 patients
with suspected TB pericarditis from Cameroon, Nigeria, and
SouthAfrica, showed that patients withHIVweremore likely
to present with dyspnea and electrocardiographic changes,
indicating myopericardial disease, and less likely to present
with ascites, suggestive of a lower incidence of constrictive
pericardial disease [38].
HIV coinfection with TB myopericarditis is a leading
cause of cardiac death among HIV-infected patients, with
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a nearly sixfold increase in mortality compared to HIV-
uninfected individuals [37]. HIV infection does not seem
to alter the response to TB pericarditis treatment, although
HIV-infected individuals have a higher rate of pericardial dis-
ease relapse [36]. The use of adjuvant corticosteroids to treat
TB pericarditis in HIV-infected population remains contro-
versial. A large, randomized controlled trial investigating the
use of corticosteroids and/or Mycobacterium indicus pranii
immunotherapy in TB pericarditis showed no difference
between prednisolone and placebo or M. indicus pranii and
placebo in the primary combined outcome of death, cardiac
tamponade, and constrictive pericarditis, though patients
receiving prednisolone as compared to placebo had signifi-
cantly lower rates of the secondary outcomes of progression
to constrictive pericarditis and fewer repeat hospitalizations
[39]. There was also a significant increase in HIV-associated
malignancy in HIV-infected patients receiving both pred-
nisolone andM. indicus pranii versus placebo [39].
3. Effects of ART on Clinical
Manifestations of HIVAC
The widespread use of ART has changed the phenotype
of HIVAC as subclinical cardiac abnormalities, including
diastolic dysfunction and impaired cardiac strain patterns,
become increasingly common in HIV-infected individuals
on effective HIV treatment [40]. A growing prevalence
of asymptomatic ventricular dysfunction, abnormal strain
patterns, and a higher incidence of diastolic dysfunction
has been noted in HIV-infected populations on ART. The
prevalence of systolic dysfunction has decreased in HICs
whereas diastolic dysfunction is now seen in up to 64%
of asymptomatic HIV-infected patients on ART [6, 40,
41]. Magnetic resonance imaging studies suggest that these
subclinical changes may be due in part to myocardial fibrosis
and steatosis seen in patients on ART [42]. While ART has
dramatically reduced the burden of HIVAC in HICs, the
incidence and mortality rates have risen in LMICs [14].
3.1. Burden of HIVAC in HICs. Most of our understanding
of HIVAC emanates from studies performed in HICs, mostly
from the United States and throughout Europe. Since the
widespread initiation of ART the prevalence of HIVAC has
dropped by 30% in these regions [14]. In the late 1980s,
roughly one-third of all HIV-related cardiac deaths were
due to dilated cardiomyopathy, and autopsy studies found
evidence of myocarditis in up to 40% of noncardiac deaths
in HIV-infected patients [35, 43]. A prospective study out of
Johns Hopkins University in the early 1990s estimated the
incidence of global left ventricular dysfunction to be 18% per
year in HIV-infected patients [43]. However, with consistent
access to antiretroviral medication and early initiation of
treatment, myocarditis and dilated cardiomyopathy have
virtually disappeared as manifestations of cardiac disease in
HIV-infected patients in HICs today.
With the early advent of ART in HICs, the incidence of
systolic dysfunction has decreased but diastolic abnormalities
are increasing. A 2013 meta-analysis of 11 studies from HICs
revealed that, among 2242 HIV-infected individuals on ART,
only 8.3% had left ventricular systolic dysfunction whereas
43.4% had evidence of diastolic dysfunction [44]. Higher
rates of subclinical cardiac abnormalities, such as abnormal
left ventricular relaxation or pseudonormal filling patterns,
higher pulmonary artery pressure, and decreased exercise tol-
erance aremore frequently observed in patients on ART [40].
Additionally, the burden of cardiac disease in HIV infec-
tion in HICs are transitioning towards increasing atheroscle-
rosis and ischemic heart disease. Patients on ART in HICs
are living longer and exposed to more traditional cardiac risk
factors such as tobacco use, hyperlipidemia, and diabetes.
Antiretroviral therapies have been linked to an increased
risk of coronary artery disease and myocardial infarction
as well as acceleration of atherosclerotic formation and
metabolic disturbances. Generally, immune reactivation with
ART and chronic low-grade inflammation have been shown
to promote subclinical atherosclerotic changes and arterial
stiffness [45, 46]. The three major classes of ART, protease
inhibitors (PIs), nucleoside reverse transcriptase inhibitors
(NRTIs), and nonnucleoside reverse transcriptase inhibitors
(NNRTIs), have all been associated with some degree of dys-
lipidemia; PIs and the NRTIs, stavudine and zidovudine, are
indirectly implicated in the development of atherosclerosis
via significant alterations in lipid metabolism and insulin
resistance [45, 47, 48]. The Data Collection on Adverse
Events of Anti-HIV Drugs (D:A:D) study, an international
collaboration representing over 30,000HIV-infected patients
across Europe, the United States, and Australia, found an
increased risk of myocardial infarction with use of PIs and
certain NRTIs, namely, abacavir and didanosine [45, 49–51].
However, a 2013 systematic review of 27 studies addressing
the risk of cardiovascular disease from ART did not find a
consistent relationship between these drugs and myocardial
risk [52]. Further prospective, randomized controlled trials
are needed to better assess the relationship between ART
and myocardial infarction risk. Meanwhile, the long term
benefits of ART on controlling HIV infection and disease
sequelae are thought to outweigh the increased relative risk
of cardiovascular disease in the HIV-infected population.
3.2. Burden of HIVAC in LMICs. The impact of HIVAC may
be most severe in LMICs, where HIVAC remains a relevant
cause ofmorbidity andmortality despite the expanding use of
ART [4]. HIVAC is associatedwith low socioeconomic status,
a longer duration of HIV infection, low total lymphocyte
count, low CD4 count, high HIV-1 viral load, and low plasma
levels of selenium [37]. A CD4 count <100 cells/mm3 appears
to be an important threshold belowwhich the risk of develop-
ingHIVAC increases significantly [5]. Cross-sectional studies
in the pre-ART era from SSA indicated a prevalence of
cardiomyopathy in up to 57% in hospitalized patients [35]. A
prospective study of 157 HIV- infected patients in Kinshasa,
Democratic Republic of Congo, showed that about half of the
patients developed a cardiac abnormality over 7 years [13].
More recently, the Heart of Soweto study found that, of
the 5328 newly diagnosed cases of cardiac disease at a major
hospital in South Africa between 2006 and 2008, 518 cases
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were in HIV-infected patients and only half of them (54%)
were taking ART [7]. The most common cardiac diagnosis
among all HIV-infected patients was HIVAC (38%) with an
average left ventricular ejection fraction of 46%. The viral
loads were significantly higher (110,000 versus 90,000 RNA
copies/mL) and CD4 counts significantly lower (180 versus
211 cells/mm3) in cases of HIVAC compared to those HIV-
infected patients without cardiomyopathy [7]. Results from
the Sub-Saharan Africa Survey of Heart Failure study, a
multinational registry of patients across Africa presenting to
hospitals with acute, decompensated heart failure, showed
that HIV was the direct cause of heart failure in 2.6% of all
cases [53].
The mortality due to HIVAC is significant and reaches as
high as 15–20% in parts of SSA [54]. HIV status is an inde-
pendent predictor of death at 180 days for patients with acute
decompensated heart failure and is associated with increased
in-hospital, 60-day, and 180-day mortality rates [55].
3.3. Reconciling HIVAC Disparities in HICs and LMICs.
The causes contributing to HIVAC seem to depend on the
degree of viral suppression which are strongly related to
region of the world [35]. Opportunistic and viral infections,
nutritional deficiencies, and direct HIV toxicity are leading
causes in uncontrolled disease, especially with high viral
loads or CD4 counts <100 [4]. When viral suppression is
adequate and immune function is restored, ART, chronic
inflammation, and autoimmunity may be more pronounced
contributors toHIVAC [4].Thus, HIVACmay truly represent
yet another syndrome of heart failure with numerous indi-
vidual causes, each of which may warrant specific therapy
in addition to generally accepted therapy for heart failure.
As life expectancy for HIV-infected individuals continues
to increase worldwide, we are likely to see more subclinical
manifestations of HIVAC which warrant more attention to
screening in the presymptomatic individual.
4. Current Diagnostic and Screening Tools
Identifying early markers of myocardial dysfunction in HIV-
infected individuals at high risk of cardiac disease may
provide early intervention of life-saving therapy. To date,
however, there have been no diagnostic criteria or screening
guidelines defined for HIVAC. Echocardiography remains
the standard for detection of ventricular dysfunction [56].
Diastolic dysfunction and abnormal myocardial strain are
often the only echocardiographic abnormalities in asymp-
tomatic HIV-infected patients on ART [4]. Early detection
of subclinical myocardial dysfunction can be assessed by 2-
dimensional strain and strain rate using speckle tracking
echocardiography [37]. Further, cardiac magnetic resonance
can now detect signs of subclinical cardiac steatosis and
myocardial fibrosis [42]. However, the clinical significance
of some of these structural and metabolic cardiac changes
remains unknown.
The role of screening echocardiography in HIV-
infected populations is unclear. Timing and frequency of
echocardiography testing is undetermined. Starc et al. have
recommended that pediatric patients have an echocardio-
gram done at the time of HIV-diagnosis, followed by repeat
testing every couple of years for asymptomatic patients
or annual testing in patients with symptoms of heart
failure, unexplained respiratory illness, or symptomatic HIV
infection [57]. Given the increasing prevalence of subclinical
disease and poor outcomes in late detection of systolic
dysfunction in HIV-infected patients, developing clear
screening guidelines should be a high priority. However,
even with optimized screening practices and diagnostic
criteria, targeted treatment options remain limited once
HIVAC develops.
5. Current Treatment Options
Best practices for treatment of HIVAC have not been rig-
orously tested. Early initiation of beta-blockers and ACE-
inhibitor therapy may be beneficial in subclinical disease to
prevent progression to severe systolic dysfunction through
common mechanisms, such as afterload reduction and sym-
pathoadrenal modulation [56, 58]. In the absence of specific
guidelines to the contrary, patients withHIV and heart failure
should be treated with standard therapy for heart failure
according to current consensus guidelines [59].
ART has been shown to positively impact outcomes in
retrospective studies, but there is no prospective evidence
that ART has a beneficial effect on cardiac outcomes in
HIVAC [20]. Such evidence is unlikely to be forthcoming,
however, as the latest WHO guidelines recommend initiating
ART regardless of CD4 count. Adjunctive therapies for
HIVAC such as supplementation with carnitine, selenium,
and multivitamins have been proposed in an attempt to
preserve left ventricular function in micronutrient deficient
populations but warrant further evidence before wide scale
adoption [60]. Immunomodulatory therapy has been shown
to improve left ventricular structure and function in some
patient populations. Patients with biopsy-proven autoim-
mune myocarditis, for example, improve left ventricular
function and dimensions after therapy with corticosteroids
[61]. Monthly intravenous immunoglobulin (IVIG) infusions
have also been shown to improve cardiac function in HIV-
infected children with subclinical cardiac abnormalities [20,
62]. However, there are no controlled trials investigating
efficacy of corticosteroids or IVIG in treating HIVAC in adult
populations. Further investigation is needed to identify best
treatment practices for HIVAC.
Mechanical support devices and cardiac transplanta-
tion are definitive treatment options for end-stage HIVAC,
although their use is still limited inHIV-infected populations.
HIV infection was previously considered a contraindication
to mechanical support and transplant, but since advanced
ART has improved outcomes and mortality rates from end-
stage heart failure continue to rise, the United Network for
Organ Sharing (UNOS) declared that asymptomatic HIV-
infected individuals should not be excluded from heart trans-
plant consideration solely based on their HIV status [63].
Data from case series and small cohort studies in theUSA and
Canada suggest that good outcomes with survival rates for
HIV-infected patients are similar to those of HIV-uninfected
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patients up to 3 years after cardiac transplantation [64, 65].
Despite this evidence, a recent survey of cardiac transplanta-
tion centers found that 57% of programmes still considered
HIV infection to be a contraindication to transplantation
due to scarcity of organ supply, concerns for posttransplant
immunosuppression enhancing progression to AIDS, and
possible postoperative drug interactions between ART and
immunosuppressive therapies [66]. Left ventricular assist
devices (LVADs) are also scarcely used in HIV-infected
individuals, with most centers citing risks of device-related
infection [66]. A case study of two HIV-infected individuals
who underwent implantation with HeartMate XVE pulsatile-
flow LVAD found no HIV-related infectious complications,
and a recent analysis of all 22 HIV-infected LVAD cases in
the USA revealed outcomes similar to the general LVAD
population with comparable mortality rates at 3, 6, 12, and
24 months [66, 67].
6. Biomarkers for HIVAC Screening
The use of novel biomarker testing to screen for cardiac
dysfunction in HIV-infected persons is a growing area of
investigation. B-natriuretic peptide (BNP) screening com-
bined with collaborative care has been shown to reduce the
rates of systolic and diastolic dysfunction in patients at risk
of heart failure [68]. An inverse correlation between BNP
levels and left ventricular function in HIV-infected patients
has been seen in small case studies [69, 70], but the specificity
of BNP for cardiac disease in HIV-infected individuals is
unclear [69–71]. More research is needed to assess whether
this cost-effective and simple test may be a useful screening
tool for identifying HIVAC.
Soluble ST2, a novel biomarker of cardiac stress, and
GDF-15, a growth differentiation factor expressed in cardiac
injury, are associated with cardiac dysfunction and all-cause
mortality in a controlled study of HIV-infected individuals
[72]. ST2 was also associated with diastolic dysfunction, sug-
gesting its role as a possible profibrotic mediator in HIVAC.
Other novel markers requiring further investigation include
serum autoantibody titers for cardiac-specific autoantibod-
ies, like anti-alpha myosin, that have been identified in left
ventricular dysfunction in HIV-infected individuals andmay
serve as a target for immunomodulatory treatment [10].
7. Conclusion
HIV-associated cardiomyopathy remains a significant cause
of morbidity and mortality in both HICs and LMICs despite
the widespread use of ART. Overall, the clinical presentation
of HIVAC is changing as life expectancy increases in HIV-
infected individuals. Severe, symptomatic dilated cardiomy-
opathy, as previously seen in end-stage AIDS, is declining as
the predominant clinical manifestation of HIVAC. Subclin-
ical, diastolic dysfunction and abnormal ventricular strain
patterns are being seen more frequently in HIV-infected
individuals with adequate HIV viral control. The etiology for
this variable phenotype likely depends on the degree of viral
replication and immunosuppression. Myocarditis, oppor-
tunistic infections, micronutrient deficiencies, and HIV itself
play a large role in individuals with inadequate viral sup-
pression and poor immune function, whereas ART toxicity
and cardiac autoimmunity are seen more when disease is
controlled.
The prevalence of HIVAC has declined in HICs with suc-
cessful ART and decreased opportunistic infections, whereas
HIVAC remains a significant contributor to disease burden
in LMICs [7, 14, 27]. These diverging epidemics result from
a combination of factors. Poor soil composition across SSA
has predisposed a quarter of the population to selenium
and other micronutrient deficiencies that have been seen to
worsen cardiomyopathy [4]. Limited access to effective ART
is a critical challenge faced in many LMICs. Frequent use
of AZT in first-line therapy persists in many LMICs due to
its low cost despite international recommendations for other,
less cardiotoxic regimens [73].
Emphasis needs to be placed on designing clear guide-
lines for screening protocols and diagnostic criteria for
HIVAC. Appropriate timing and tools for cardiac screen-
ing in HIV-infected individuals beg clarification. Using
advanced echocardiographic imaging to evaluate for con-
tractile reserve, diastolic dysfunction, and abnormalities in
myocardial deformation can identify higher-risk patients
[4], but it remains unknown whether this alters clinical
decisionmaking forHIV-infected patients. Establishing diag-
nostic criteria that account for stage of HIV and degree of
immunosuppression should be a high priority. Recommen-
dations regarding the timing and frequency of routine cardiac
evaluation for HIV-infected individuals are needed, as well
as partnership between infectious disease specialists and
cardiologists in identifying and managing patients at high
risk ofHIVAC.HIV-associated cardiomyopathywill continue
to be a significant contributor to the global cardiac disease
burden as the HIV population ages, and more research is
needed to understand best practices in diagnosis and treating
the disease worldwide.
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